-2.38%
-25.52%
-42.77%
-54.01%
-52.87%
-42.46%
-49.76%
AI Spotlight on IMTX
Company Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States.The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell.
The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors.It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate.The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications.
Immatics N.V. is headquartered in Tübingen, Germany.
Market Data
| Last Price | 5.34 |
| Change Percentage | -2.38% |
| Open | 5.35 |
| Previous Close | 5.47 |
| Market Cap ( Millions) | 637 |
| Volume | 80244 |
| Year High | 13.77 |
| Year Low | 5.22 |
| M A 50 | 6.9 |
| M A 200 | 10.1 |
Financial Ratios
| FCF Yield | -7.20% |
| Dividend Yield | 0.00% |
| ROE | -15.98% |
| Debt / Equity | 4.19% |
| Net Debt / EBIDTA | 358.75% |
| Price To Book | 1.31 |
| Price Earnings Ratio | -9.0 |
| Price To FCF | -13.88 |
| Price To sales | 5.37 |
| EV / EBITDA | -9.28 |
News
- Jan -09 - New Strong Buy Stocks for January 9th
- Nov -18 - What Makes Immatics (IMTX) a New Buy Stock
- Nov -18 - Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates
- Nov -18 - Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
- Nov -08 - Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
- Nov -05 - Immatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy?
- Oct -12 - Immatics: A Promising TCR Pipeline
- Oct -11 - Immatics Announces Pricing of $150 Million Public Offering
- Oct -10 - Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?
- Oct -10 - Immatics Announces Proposed $150 Million Public Offering
- Oct -10 - Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
- Oct -04 - Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
- Sep -16 - Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
- Sep -06 - Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
- Aug -13 - Immatics (IMTX) Reports Q2 Loss, Tops Revenue Estimates
- Aug -13 - Immatics Announces Second Quarter 2024 Financial Results and Business Update
- Jul -22 - Wall Street Analysts Predict a 54.95% Upside in Immatics (IMTX): Here's What You Should Know
- Jul -22 - Here's Why 'Trend' Investors Would Love Betting on Immatics (IMTX)
- May -14 - Immatics (IMTX) Reports Q1 Loss, Tops Revenue Estimates
- May -14 - Immatics Announces First Quarter 2024 Financial Results and Business Update
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> T Cell Redirecting Immunotherapies
Expected Growth : 10.0 %
What the company do ?
T Cell Redirecting Immunotherapies from Immatics N.V. are cancer treatments that harness the power of a patient's own immune system to fight cancer, using T cells to recognize and attack cancer cells.
Why we expect these perspectives ?
Immatics N.V.'s T Cell Redirecting Immunotherapies growth is driven by increasing adoption in cancer treatment, strong clinical trial results, and strategic partnerships. Rising cancer incidence, growing demand for targeted therapies, and expanding pipeline of novel targets also contribute to the 10.0% growth.
Immatics N.V. Products
| Product Range | What is it ? |
|---|---|
| ACTengine | A proprietary cell therapy platform that leverages gamma delta T cells to target and kill cancer cells |
| TCR-T cell therapy | A type of immunotherapy that uses T cells engineered to recognize and target specific tumor antigens |
| Target Warehouse | A comprehensive database of tumor-specific targets and peptides for cancer immunotherapy |
| XPRESIDENT | A proprietary platform for the discovery and validation of novel tumor-specific targets and peptides |
Immatics N.V.'s Porter Forces
Threat Of Substitutes
Immatics N.V. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the field of immunotherapy.
Bargaining Power Of Customers
Immatics N.V. has a diverse customer base, and no single customer has significant bargaining power, reducing the threat of customer bargaining power.
Bargaining Power Of Suppliers
Immatics N.V. relies on a few key suppliers for raw materials and equipment, giving them some bargaining power, but the company's strong relationships with suppliers mitigate this threat.
Threat Of New Entrants
The biotechnology industry is highly competitive, and new entrants can easily disrupt the market, posing a significant threat to Immatics N.V.'s market share.
Intensity Of Rivalry
The immunotherapy market is highly competitive, with many established players and new entrants vying for market share, leading to a high intensity of rivalry.
Strength
Capital Structure
| Value | |
|---|---|
| Debt Weight | 6.40% |
| Debt Cost | 5.35% |
| Equity Weight | 93.60% |
| Equity Cost | 7.37% |
| WACC | 7.24% |
| Leverage | 6.84% |
Immatics N.V. : Quality Control
Immatics N.V. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| BRNS | Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing … |
| IDIA.SW | Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, … |
| ACIU | AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen … |
| RVU.WA | Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with … |
| GNS.L | Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Barinthus Bio
A-Score
1-Year Total Return ->
🥈
Idorsia
A-Score
1-Year Total Return ->
🥉
AC Immune
A-Score
1-Year Total Return ->
4
Immatics
A-Score
1-Year Total Return ->
5
Ryvu Therapeutics
A-Score
1-Year Total Return ->
6
